Xenon Pharma amends inducement plan, increases share reserve to 900,000

Xenon Pharmaceuticals Inc.

Amended 2025 Inducement Plan on Nov 24, 2025, increasing share reserve from 775,000 to 900,000 common shares.
Plan is exclusively for inducing new employees or rehires after a bona fide interruption of employment.
No shareholder approval sought under Nasdaq Listing Rule 5635(c)(4); plan meets inducement grant rules.
Awards include nonstatutory stock options, SARs, restricted stock units, restricted stock, and performance awards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.